| Species |
Human |
| Protein Construction |
PD-L1/B7-H1 (Phe19-Arg238)_x000D_
Accession # Q9NZQ7-1 |
Llama Fc |
| N-term |
C-term |
|
| Purity |
> 95% as determined by BisTris PAGE
> 95% as determined by HPLC |
| Endotoxin Level |
Less than 1EU per μg by the LAL method. |
| Biological Activity |
Measured by its binding ability in a functional ELISA. Immobilized PD-L1/B7-H1, Llama Fc Chimera, Human at 5μg/ml (100μl/well) on the plate can bind Human PD1, mFc Tag. Test result was comparable to standard batch. |
| Expression System |
HEK293 |
| Theoretical Molecular Weight |
52.50 kDa |
| Apparent Molecular Weight |
Due to glycosylation, the protein migrates to 65-75 kDa based on Bis-Tris PAGE result. |
| Formulation |
Lyophilized from 0.22 μm filtered solution in PBS (pH 7.4). |
| Reconstitution |
Centrifuge the tube before opening. Reconstituting to a concentration more than 100 μg/ml is recommended. Dissolve the lyophilized protein in distilled water. |
| Storage & Stability |
Upon receiving, the product remains stable up to 6 months at -20 °C or below. Upon reconstitution, the product should be stable for 3 months at -80 °C. Avoid repeated freeze-thaw cycles. |
| Target Background |
B7-H1, also known as PD-L1 and CD274, is an approximately 65 kDa transmembrane glycoprotein in the B7 family of immune regulatory molecules. PD-L1 has been identified as the ligand for the immunoinhibitory receptor programmed death-1(PD1/PDCD1) and has been demonstrated to play a role in the regulation of immune responses and peripheral tolerance. |
| Synonyms |
CD274; PDL1; PD-L1; PD-L1B7 homolog 1;B7-H; B7H1; B7-H1; PDCD1L1; PDCD1LG1 |
For research use only. Not intended for human or animal clinical trials, therapeutic or diagnostic use.
